IBX 13.1% 5.3¢ imagion biosystems limited

Ann: Imagion to complete the MagSense HER2 Phase 1 Study, page-4

  1. 264 Posts.
    lightbulb Created with Sketch. 70
    In March 2023 the Company received feedback from the FDA pertaining to its clinical development plans and intent to proceed with a mul-site Phase 2 study in the U.S. The Phase 2 study will be used to opmize dose and imaging schedules as well as explore various endpoints for clinical validity.
 
watchlist Created with Sketch. Add IBX (ASX) to my watchlist
(20min delay)
Last
5.3¢
Change
-0.008(13.1%)
Mkt cap ! $2.099M
Open High Low Value Volume
6.0¢ 6.0¢ 5.3¢ $5.718K 99.96K

Buyers (Bids)

No. Vol. Price($)
3 115001 5.2¢
 

Sellers (Offers)

Price($) Vol. No.
5.3¢ 1102 1
View Market Depth
Last trade - 12.21pm 23/07/2024 (20 minute delay) ?
IBX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.